Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abbott
With
Abbott Japan Co.,Ltd
The first 12-week period in this study was a dose-response study reported as Study M10-309 (NCT00667576). Only subjects who completed 12 weeks in NCT00667576 were enrolled into this study (M10-312). Baseline in this study was the same as Baseline in NCT00667576. The duration of treatment in Study M10-312 was 40 weeks (for a total of 52 weeks, including NCT00667576).
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who completed 12 weeks of Study M10-309 (NCT00667576).
You may not be if
Patients taking drugs that affect intact parathyroid hormone (iPTH), calcium, or bone metabolism.
Patients with progressive malignancy or clinically significant hepatic disease.
Patients who developed severe cerebrovascular/cardiovascular disease during the dose-response portion of the study (i.e., during M10-309, NCT00667576).
Patients with uncontrolled diabetes during the dose-response portion of the study (i.e., during M10-309, NCT00667576).
